Details of the Drug Reposition

General Information of This Drug (ID: DMBPY9Z)

Drug Name
MBG453   DMBPY9Z

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 3 [1]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1/2 [2]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04266301) Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2) (STIMULUS-MDS2). U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)